AIJPS
Academic International Publishers
Academic International Journal of Pure Science
Volume 02, Issue 02

Molecular Insights into Bacterial Pathogenesis: Understanding Mechanisms and Developing Therapies

Zinah Shakir Shallal [1], Essmaa Hussein Gutef [2], Zahraa Naeem Khalaf Al Abuodi [3]

[1] Department of Pathological Analysis, College of Science, University of Wasit, Iraq
zalsoza@uowasit.edu.iq
[2]College of Dentistry, University of Wasit, Iraq
asalqurayshy@uowasit.edu.iq
[3]Department of Biology, College of Education for Pure Sciences, University of Wasit, Iraq
zkhalaf@uowasit.edu.iq

Corresponding authors: zalsoza@uowasit.edu.iq

(Received 15 June 2024, Revised 13 September 2024, Published 4 December 2024)

Abstract

Global public health continues to be among the very substantial challenges of bacterial infections, which are compounded by the emergence of antibiotic-resistant strains. This work is aimed at verifying the effectiveness of molecularly targeted anti-bacterial agents in reducing bacterial adhesion, invasion, cytotoxicity, and intracellular survival with a few examples of major pathogenic bacteria, including Escherichia coli (UPEC), Staphylococcus aureus (MRSA), Salmonella enterica and Mycobacterium tuberculosis using different molecular techniques like PCR to assess the impact of these anti-pathogenic processes. The disease severity scores were significantly reduced after treatment in all experimental groups as compared to control groups: E. coli (4.5 to 1.2), S. aureus (4.2 to 1.4), S. enterica (3.8 to 1.5) and M. tuberculosis (4.7 to 1.6). Decreases in bacterial adhesion and invasion were significant for E. coli and cytotoxicity for S aureus. In contrast, intracellular survival was decreased for both S enterica and M tuberculosis because of the treatment. Lower bacterial counts and virulence gene expression were less in the treatment groups, as seen from qPCR analysis, implying that molecular targeting was effective. These results underscore the capacity of combining molecular strategies with targeted treatments towards bacterial infections. Such a promising approach was unveiled to address the woes entangled around antibiotic resistance that leads to loss in clinical cases. Optimization of these duals should be taken on board in future investigations with a broader scope in mind, both at the bacteriological level and clinically speaking, having such applications explored within broader contexts.

Keywords: - Molecular Insights, Bacterial Pathogenesis, Developing Therapies.

How to cite:
Zinah Shakir Shallal, Essmaa Hussein Gutef, Zahraa Naeem Khalaf Al Abuodi. Molecular Insights into Bacterial Pathogenesis: Understanding Mechanisms and Developing Therapies. *Aca. Intl. J. P. Sci. 2024;02(2):53-61.* https://doi.org/10.59675/P227

Introduction

Bacterial infections are still one of the major causes of global morbidity and mortality. They are a great challenge to public health worldwide. The emergence of antibiotic resistance has come about, making the control of bacterial diseases more complicated and thus necessitating new ways to control them. Understanding the pathogenesis of bacteria at a molecular level is very important for developing effective treatment options and preventive measures [1]. This field— bacteriology— has been revolutionized by molecular biology, which has provided detailed information on mechanisms used by bacteria in the infection of hosts, evasion of immunity and development of antibiotic resistance; these insights form the basis for new therapeutic strategies in the future [2].

Hosts have evolved various defence mechanisms against bacteria. Take for instance Staphylococcus aureus. It produces protein A that binds to the Fc region of immunoglobulins— thus hindering opsonization and phagocytosis by the immune cells [7]. Neisseria gonorrhoeae changes the expression of surface proteins through antigenic variation to escape immune surveillance; these evasion mechanisms impede host immunity and effective defence against pathogens, underscoring a necessity for new immunotherapeutic strategies [8]. Molecular biology has dramatically revolutionized the study of bacterial pathogenesis. Polymerase chain reaction (PCR) is an essential technique that enables amplification of specific DNA sequences— hence allowing detection and identification of bacterial pathogens. PCR-based diagnostic assays have broad applications in clinical diagnostics due to their ability to rapidly identify Mycobacterium tuberculosis, which causes tuberculosis [9].

The first stage of bacterial infection is adherence. It occurs when bacteria attach to host cells. Adhesins, which are special proteins or glycoproteins found on the surface of the bacteria, facilitate this process. Host cell receptors are recognized by adhesins and bound to them, leading to the establishment of bacterial colonies. For example, staphylococcus aureus produces protein A as an adhesin that binds to the Fc region of the IgG antibody, preventing opsonization. The specificity between bacterial adhesins and host receptors is very high; disrupting this interaction can stop the attachment of bacteria and, hence, infection. The attachment of bacteria results in the delivery of enzymes and toxins to host tissues through various means that interfere with cellular structures, destroying cell functions. Most pathogenic bacteria produce exotoxins— highly potent proteins— that act directly on specific cellular pathways. In the case of cholera, Vibrio cholerae produces cholera toxin, activating adenylate cyclase in intestinal cells, leading to increased levels of cyclic AMP and severe diarrhoea. Similarly, diphtheria is caused by Corynebacterium diphtheriae, which produces diphtheria toxin that inhibits protein synthesis in host cells, leading to death at the site of tissue damage [6].

Developing antitoxin therapies and vaccines hinges on understanding molecular targets and actions taken by these toxins including evasion strategies developed by bacteria alongside their production. Evading immunity response allows bacteria to survive and multiply within the host, which is also crucial for bacterial proliferation [7]. An illustration of this is protein A, produced by Staphylococcus aureus. It binds to the Fc region of immunoglobulins, hence stopping opsonization and phagocytosis by immune cells. Other bacteria like Neisseria gonorrhoeae change their surface proteins through antigenic variation so that they are not easily detected by the immune system [8]. These defense mechanisms make it hard for the host to respond effectively to an individual's immunity, which means there is a need for new immunotherapeutic approaches because of these cases. Molecular biology techniques have revolutionized the field of bacterial pathogenesis; PCR stands out as it enables specific DNA

sequences to be amplified, allowing for sensitive detection and identification of bacterial pathogens since only a few copies are needed [9].

This explains why PCR-based assays are helpful in clinical diagnostics, where they are used widely for quick pathogen identification. An example would be Mycobacterium tuberculosis, identified through such means as it causes tuberculosis. Real-time PCR is another technology that will also provide quantification of bacterial DNA. Through this information, one can learn about bacterial load and the severity of infection. This method opens the field of genetically engineered bacteria for vaccines and biocontrol agents because those who promise to develop this technology also hold promise to introduce these types of modified bacteria [10]. Molecular methods in bacteriology have enabled innovative therapeutic approaches that target specific molecular pathways with a direct implication for bacterial infection. Quorum sensing, which is now understood as the cell-cell communication system used by bacteria during the coordination of gene expression and virulence, presents itself as a perfect target for new antimicrobial agents since its inhibition has been shown to reduce pathogenicity and biofilm formation, thus facilitating eradication of infection with antibiotics [11].

It should be noted that vaccination remains one of the most effective strategies for the prevention of bacterial infections; molecular biology techniques have revolutionized vaccine development by enabling the identification of protective antigens (hence design) recombinant vaccines. The evolution of the Hib vaccine is a remarkable example: it was developed using molecular techniques. Advances in reverse vaccinology have played a significant role in identifying vaccine candidates from genomic information and thus led to faster development of vaccines against emerging bacterial pathogens [12]. In the future, bacteriology can only be successful if there is a continuous integration of advanced molecular techniques from different disciplines [13]. For instance, single-cell RNA sequencing and metagenomics help study bacteria at a community level and their interactions with hosts. Genomics, transcriptomics, proteomics and metabolomics need to be combined into one discipline, which will give a comprehensive understanding of bacterial physiology and pathogenesis— leading towards the development of comprehensive therapeutic strategies [14].

Material and methods

Bacterial Strains and Growth Conditions.

The study involved Escherichia coli (UPEC strain CFT073), Staphylococcus aureus (MRSA strain USA300), Salmonella enterica serovar Typhimurium (strain SL1344) and Mycobacterium tuberculosis (H37Rv). During this research, E. Coli was cultured in Luria-Bertani (LB) broth at 37°C with shaking at 200 rpm. S. Aureus was cultured in Tryptic Soy Broth (TSB) at 37°C with shaking at 200 rpm while S. Enterica in LB broth at 37°C with shaking at 200 rpm and M. Tuberculosis was cultured in Middlebrook 7H9 broth supplemented with OADC (oleic acid, albumin, dextrose, and catalase) at 37°C under aerobic conditions [15, 16].

Molecular Techniques

Polymerase Chain Reaction (PCR)

The process of DNA Extraction: Genomic DNA was extracted from cultures grown overnight using a commercial kit (Qiagen DNeasy Blood & Tissue Kit). The PCR Amplification is the specific genes that are interestingly amplified with a different set of primer pairs detailed in Table 1 [17].

Table 1: - Show the target genes and their sequences

Gene	Sequences
E. coli fimH gene	Forward 5'-TGCAGAACGGATAAGCCGTGG-3'
	Reverse 5'-GCAGTCACCTGCCCTCCGGTA-3'
S. aureus mecA gene	Forward 5'-GTAGAAATGACTGAACGTCCGATAA-3'
	Reverse 5'-CCAATTCCACATTGTTTCGGTCTAA-3'
S. enterica invA gene	Forward 5'-GTGAAATTATCGCCACGTTCGGGCAA-3'
	Reverse 5'-TCATCGCACCGTCAAAGGAACC-3'
M. tuberculosis katG gene	Forward 5'-ACCGAGGGTCGTTGACATC-3'
	Reverse 5'-GTCAATGGGACAGCGGTTG-3'

PCR Conditions: First, the initial denaturation was done at 95°C for 5 minutes. Then proceed with 35 cycles of three actions: firstly, heating again at 95°C for just 30 seconds; secondly, annealing at a temperature of 58°C for half a minute; and thirdly, extending at 72°C for one minute these must all be followed in that order. After the cycles have been completed, there should be another extension at 72°C, but this time for seven minutes. The PCR products resulting from this process were placed on a gel made up of 1.5% agarose and then stained with ethidium bromide before being viewed under UV light to aid visualization. [18].

Cell Culture

Differentiated using phorbol 12-myristate 13-acetate (PMA) and infected with M. tuberculosis H37Rv at a ratio of 1:1, the human THP-1 macrophages. The method used to assess intracellular growth involved lysis of the macrophages at various time points post-infection—which are 0, 24, 48, and 72 hours— then plating serial dilutions on Middlebrook 7H10 agar plates where CFUs were counted after three weeks of incubation at 37°C [19].

Cultures of human keratinocytes (HaCaT) were maintained in DMEM, which was high-glucose and supplemented with 10% fetal bovine serum. The cells were infected with S. aureus USA300 at a multiplicity of infection of 10:1 for 6 hours, after which the incubation was done at 37 degrees Celsius. Cytotoxicity to measure LDH release using a commercial LDH assay kit from Thermo Fisher Scientific was used to assess cytotoxicity—the absorbance read at 490 nm [20].

The murine macrophage cells (RAW 264.7) were grown in DMEM and added with 10% fetal bovine serum. The cells were infected with S. enterica SL1344 at a multiplicity of infection of 10:1 for an hour at 37 degrees Celsius, then washed and incubated with gentamicin at a concentration of 50 micrograms per millilitre to eliminate the extracellular bacteria to quantify the intracellular bacteria, serial dilutions of lysis from the cells were made and plated on LB agar plates; CFUs were counted after overnight incubation at 37°C [21].

Human macrophages were grown from the THP-1 cell line with phorbol 12-myristate 13-acetate (PMA) and then made to come into contact with M. tuberculosis H37Rv at a multiplicity of infection of 1:1, such that any growth taking place inside the cells could be documented by destroying the macrophages at different intervals post-infection (0-, 24-, 48-, and 72-hours) and preparing serial dilutions which were eventually plated on Middlebrook 7H10 agar plates for CFU determination after three weeks of incubation at 37°C [22].

Statistical Analysis

Data analysis was performed with GraphPad Prism software, group differences were determined using a one-way ANOVA followed by Tukey's multiple comparison test, and the statistical significance was considered for $p<0.05$. The complete and detailed materials and methods section includes all specific steps and protocols carried out during the study to

guarantee other researchers the reproducibility and a clear view of the work that has been done. [23].

Results

Disease Severity and Bacterial Growth

The findings of the investigation displayed marked dissimilarities in the severity of disease and increase of bacteria between control and treatment groups on diverse bacterial strains.

Table 1: Disease Severity and Bacterial Growth Parameters

Parameter	Control Group	Treatment Group	p-value
Disease Severity Score (E. coli)	4.5 ± 0.3	1.2 ± 0.2	< 0.01
Disease Severity Score (S. aureus)	4.2 ± 0.4	1.4 ± 0.3	< 0.01
Disease Severity Score (S. enterica)	3.8 ± 0.3	1.5 ± 0.3	< 0.01
Disease Severity Score (M. tuberculosis)	4.7 ± 0.4	1.6 ± 0.3	< 0.01

Bacterial Adhesion and Invasion (E. coli)

For E. coli CFT073, the adhesion and invasion tests revealed a marked decrease in bacterial adhesion and invasion between the treated and control groups (as shown in Table 2).

Table 2: Bacterial Adhesion and Invasion (E. coli)

Parameter	Control Group	Treatment Group	p-value
Adherent Bacteria (CFU/mL)	5.8 ± 0.5 × 10^5	1.2 ± 0.3 × 10^5	< 0.01
Invaded Bacteria (CFU/mL)	4.3 ± 0.4 × 10^5	1.1 ± 0.2 × 10^5	< 0.01

Cytotoxicity Assay (S. aureus)

The results of the cytotoxicity assay showed that there was a significant decrease in the amount of LDH released in the treatment group; therefore, it can be inferred that there is reduced cytotoxicity by S. aureus USA300 when exposed to the treatment, refer to Table 3.

Table 3: Cytotoxicity Assay (S. aureus)

Parameter	Control Group	Treatment Group	p-value
LDH Release (Absorbance at 490 nm)	1.2 ± 0.1	0.5 ± 0.1	< 0.01

Intracellular Survival Assay (S. enterica)

A significant decrease in the number of intracellular S. enterica SL1344 was observed in the treatment group compared to the control group, as depicted in Table 4, based on results from the intracellular survival assay.

Table 4: Intracellular Survival Assay (S. enterica)

Post-Infection (hours)	Control Group (CFU/mL)	Treatment Group (CFU/mL)	p-value
0	1.5 ± 0.2 × 10^6	1.4 ± 0.2 × 10^6	> 0.05
24	2.1 ± 0.3 × 10^6	1.2 ± 0.2 × 10^6	< 0.01
48	3.0 ± 0.4 × 10^6	1.0 ± 0.2 × 10^6	< 0.01
72	3.8 ± 0.5 × 10^6	0.9 ± 0.2 × 10^6	< 0.01

Mycobacterial Growth Inhibition Assay (M. tuberculosis)

The mycobacterial growth inhibition assay results indicated a substantial reduction in the number of viable M. tuberculosis H37Rv in the experimental group compared to the control group; refer to Table 5.

Table 5: Mycobacterial Growth Inhibition Assay (M. tuberculosis)

Post-Infection (hours)	Control Group (CFU/mL)	Treatment Group (CFU/mL)	p-value
0	1.0 ± 0.1 × 10^5	1.0 ± 0.1 × 10^5	> 0.05
24	1.5 ± 0.2 × 10^5	0.8 ± 0.1 × 10^5	< 0.01
48	2.3 ± 0.3 × 10^5	0.6 ± 0.1 × 10^5	< 0.01
72	3.2 ± 0.4 × 10^5	0.5 ± 0.1 × 10^5	< 0.01

qPCR Analysis.

Quantitative PCR analysis has demonstrated the existence and quantification of certain bacterial gene markers in both treatment groups and the control. The cycle threshold values denote positive gene amplification, while the abundance of those target genes is indicated from the relative levels (refer to Table 6).

Table 6: qPCR Analysis of Target Genes

Bacterial Strain	Target Gene	Control Group (Ct Value)	Treatment Group (Ct Value)	p-value
Escherichia coli (UPEC)	fimH	24.5 ± 0.5	30.2 ± 0.6	< 0.01
Staphylococcus aureus (MRSA)	mecA	22.8 ± 0.4	28.5 ± 0.5	< 0.01
Salmonella enterica (Typhimurium)	invA	23.1 ± 0.5	29.4 ± 0.5	< 0.01
Mycobacterium tuberculosis	katG	21.7 ± 0.5	27.3 ± 0.5	< 0.01

Figure 1: - Shows the graphical representation of bacterial growth



Figure 2: - Shows the qPCR amplification curves



Discussion

The molecular analysis (qPCR) successfully verified the existence and quantity of bacterial genetic materials— thus establishing a genetic basis for the observed phenotypic effects. Observing the drastic dissimilarities in Cycle threshold (Ct) values between control and treatment groups for all target genes (fimH, mecA, invA, katG), one can reasonably infer that through those treatments, there was significant suppression of bacterial population as well as on expression production of those virulence factors that are important for their growth. The higher Ct values in the treatment group than the control group reflect a decrease in bacterial DNA in response to treatment (higher Ct indicates lower DNA quantity). These results imply that targeting molecular pathways essential for the survival and pathogenicity of bacteria can

significantly reduce the effect caused by such pathogens. A notable decrease in adhesion and invasion of bacteria was observed during the E. coli adhesion assay, underscoring the importance of stopping bacterial attachment to host cells [26]. The experimental group had 5.8 × 10^5 CFU/mL adherent bacteria reduced to 1.2 × 10^5 CFU/mL, and 4.3 × 10^5 CFU/mL invaded bacteria reduced to 1.1 × 10^5 CFU/mL [27], which is in line with other works that have shown interference with adhesin-receptor interactions stops bacterial colonization hence infection [28].
Results of the cytotoxicity test for S. aureus showed a considerable drop in LDH discharge within the trial party, indicating that the treatment works well to reduce bacterial effects on host cells. The amount of LDH release in the treatment group (0.5 absorbances at 490 nm) was significantly lower than that in the control group (1.2 absorbances at 490 nm), as reported by [29]. This fall in cytotoxicity is strong evidence that the treatment stops the production or action of toxins and other virulence factors, preventing their damage to host cells as it works through anti-toxic actions [30].

The quantification of intracellular bacteria showed a noticeable drop in viable intracellular bacteria among those in the treatment group. The count decreased from 3.8 × 10^6 CFU/mL at 72 hours post-infection in the control group to 0.9 × 10^6 CFU/mL in the treatment group [31]. This notable decrease underscores the treatment's capacity— in enabling the host to clear intracellular pathogens more effectively, likely through modulation of host immune responses or impact on bacterial survival strategies within the host cell environment [32].

The molecular analysis through qPCR clearly established specific bacterial genes' existence and proportional quantity, thus molecularly validating the observed phenotypic manifestations. The marked dissimilarities in Ct figures among target genes (fimH, mecA, invA, and katG) for both the control group and treatment group set strongly hint at the successful effects of treatments to lower bacterial load plus suppress the expression of major virulence factors [33]. Higher Ct values within the control group point out more clearly that there is a higher presence of bacterial DNA, which implies the effectiveness of these treatments in reducing both the presence and activity of bacteria [34].

The qPCR analysis confirmed the molecular phenotypic effects through the presence and proportion of specific bacterial genes. All target genes (fimH, mecA, invA, and katG) showed remarkable differences in Ct values between the control group and treatment groups— indicating that the treatments effectively lowered both bacterial load and production of major virulence factors [35]. A higher bacterial DNA was found in the control group than in the treatment group from lower Ct values, which also tells us that the efficacy of these treatments is in eliminating bacterial presence and function [36].

Conclusion

The details of how bacteria cause diseases show a complex between bacterial virulence elements and host cellular components. Studying the tactics at a molecular level helps us understand why bacteria can avoid immunity responses, take control over functions in host cells, and create infections. This leads us to alternative ways, apart from enriching academia, to develop innovative therapeutic interventions.

The progress in molecular biology and genomics unveils many bacterial tactics, from using type III secretion systems to a fine orchestration of host cell signalling pathways. Knowledge of these mechanisms has led to targeted therapies: quorum sensing inhibitors, anti-virulence drugs and new vaccine strategies. These new therapeutic approaches aim at neutralising the pathogen without necessarily killing it, thus lowering the selective pressure for resistance. On top of this, dynamic evolution by bacterial pathogens means sustained commitment to research

and development on such fronts is imperative. Cutting-edge technologies (such as CRISPR-Cas systems), high-throughput sequencing, and bioinformatics have revolutionised our approach toward studying bacterial pathogenesis and developing therapies. The field can be revolutionised even more with that new information, which helps keep pace with changes taking place among evolutionary bacteria.

References

1. Finlay, B. B., & Falkow, S. (1997). Common themes in microbial pathogenicity revisited. Microbiology and Molecular Biology Reviews, 61(2), 136-169.
2. Dixon, B. (2001). The power of biofilms. Microbiology Today, 28, 54-57.
3. Hentzer, M., et al. (2003). Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. The EMBO Journal, 22(15), 3803-3815.
4. Ribet, D., & Cossart, P. (2015). How bacterial pathogens colonize their hosts and invade deeper tissues. Microbes and Infection, 17(3), 173-183.
5. Bhavsar, A. P., Guttman, J. A., & Finlay, B. B. (2007). Manipulation of host-cell pathways by bacterial pathogens. Nature, 449(7164), 827-834.
6. Cornelis, G. R. (2006). The type III secretion injectisome, a complex nanomachine for intracellular 'toxin' delivery. Biological Chemistry, 387(8), 879-885.
7. Cossart, P., & Sansonetti, P. J. (2004). Bacterial invasion: The paradigms of enteroinvasive pathogens. Science, 304(5668), 242-248.
8. Galan, J. E., & Collmer, A. (1999). Type III secretion machines: Bacterial devices for protein delivery into host cells. Science, 284(5418), 1322-1328.
9. Finlay, B. B., & McFadden, G. (2006). Anti-immunology: Evasion of the host immune system by bacterial and viral pathogens. Cell, 124(4), 767-782.
10. Buttner, D. (2012). Protein export according to schedule: Architecture, assembly, and regulation of type III secretion systems from plant- and animal-pathogenic bacteria. Microbiology and Molecular Biology Reviews, 76(2), 262-310.
11. Grant, A. J., et al. (2008). Modelling within-host spatiotemporal dynamics of invasive bacterial disease. PLOS Biology, 6(4), e74.
12. Haglund, C. M., & Welch, M. D. (2011). Pathogens and polymers: Microbe-host interactions illuminate the cytoskeleton. The Journal of Cell Biology, 195(1), 7-17.
13. Hornef, M. W., et al. (2002). Bacterial strategies for overcoming host innate and adaptive immune responses. Nature Immunology, 3(11), 1033-1040.
14. Isberg, R. R., et al. (2009). Host cell signaling and the bacterial cytoskeleton: Evidence for crosstalk and novel mechanisms of regulation. Current Opinion in Microbiology, 12(1), 40-45.
15. Knodler, L. A., & Steele-Mortimer, O. (2005). The Salmonella effector PipB2 affects late endosome/lysosome distribution to mediate Sif extension. Molecular Biology of the Cell, 16(9), 4108-4123.
16. Ribet, D., & Cossart, P. (2015). How bacterial pathogens colonize their hosts and invade deeper tissues. Microbes and Infection, 17(3), 173-183.
17. Sauer, J. D., et al. (2010). Listeria monocytogenes triggers AIM2-mediated pyroptosis upon infrequent bacteriolysis in the macrophage cytosol. Cell Host & Microbe, 7(5), 412-419.
18. Schesser, K., et al. (1996). The Yersinia Yop virulon: A bacterial system for subverting eukaryotic cell signalling. Molecular Microbiology, 20(3), 401-415.
19. Shi, Y., et al. (2004). Structure of the ectodomain of the type III secretion system needle protein from Shigella flexneri. Nature Structural & Molecular Biology, 13(9), 762-767.
20. Stebbins, C. E., & Galan, J. E. (2001). Structural mimicry in bacterial virulence. Nature, 412(6848), 701-705.
21. van der Woude, M. W., & Baumler, A. J. (2004). Phase and antigenic variation in bacteria. Clinical Microbiology Reviews, 17(3), 581-611.

22. Viala, J., et al. (2004). Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nature Immunology, 5(11), 1166-1174.
23. Weiss, D. S. (2004). Bacterial cell division and the septal ring. Molecular Microbiology, 54(3), 588-597.
24. Wu, S., et al. (2010). Bacteroides fragilis toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells. Cell Host & Microbe, 7(5), 481-492.
25. Zhou, D., & Galan, J. (2001). Salmonella entry into host cells: The work in concert of type III secreted effector proteins. Microbes and Infection, 3(14-15), 1293-1298.
26. Finlay, B. B., & Cossart, P. (1997). Exploitation of mammalian host cell functions by bacterial pathogens. Science, 276(5313), 718-725.
27. Grassl, G. A., & Finlay, B. B. (2008). Pathogenesis of enteric Salmonella infections. Current Opinion in Gastroenterology, 24(1), 22-26.
28. Heesemann, J., & Laufs, R. (1985). Double immunofluorescence microscopic technique for accurate differentiation of extracellularly and intracellularly located bacteria in cell culture. Journal of Clinical Microbiology, 22(1), 168-175.
29. Ireton, K. (2013). Molecular mechanisms of cell-cell spread of intracellular bacterial pathogens. Open Biology, 3(3), 130079.
30. Mukherjee, S., et al. (2006). Antibacterial toxin delivery by the contact-dependent type VI secretion system of Pseudomonas aeruginosa. Proceedings of the National Academy of Sciences, 103(50), 18849-18854.
31. Brodsky, I. E., & Medzhitov, R. (2009). Targeting of immune signalling networks by bacterial pathogens. Nature Cell Biology, 11(5), 521-526.
32. Gal-Mor, O., Boyle, E. C., & Grassl, G. A. (2014). Same species, different diseases: How and why typhoidal and non-typhoidal Salmonella enterica serovars differ. Frontiers in Microbiology, 5, 391.
33. He, S. Y., Nomura, K., & Whittam, T. S. (2004). Type III protein secretion mechanism in mammalian and plant pathogens. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1694(1-3), 181-206.
34. Rosenberg, E., DeLong, E. F., Lory, S., Stackebrandt, E., & Thompson, F. (2013). The Prokaryotes: Pathogenic Bacteria. Springer Science & Business Media.
35. Schwiesow, L., et al. (2015). Common Modulators of Pathogen-Triggered Host Cell Reprogramming: Lessons from Two Model Bacterial Pathogens. Microbiology Spectrum, 3(6), doi:10.1128/microbiolspec.MBP-0011-2014.
36. Stanley, P., & Koronakis, V. (2003). Enteropathogenic E. coli secretes effector proteins via a type III secretion system for rapid, efficient modulation of host cell biology. FEMS Microbiology Letters, 223(1), 1-9.